Sugi Predict

Sugi Predict / Compounds / SCHEMBL23675306

SCHEMBL23675306

SCHEMBL23675306

O=C(c1cnc2c(ccn2-c2cccc(C(=O)N3CCS(=O)(=O)C3)c2)c1)N1CCC(F)(F)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 7/20 0.55
▸ MGLL Q99685 1/20 0.41
▸ DDR1 Q08345 3/20 0.39
▸ CYP1A2 P05177 4/20 0.35
▸ CYP3A4 P08684 4/20 0.35
▸ USP2 O75604 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ EGFR P00533 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ CYP2D6 P10635 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HIF1A Q16665 2/20 0.35
▸ JAK2 O60674 1/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ CYP2C9 P11712 2/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ VNN1 O95497 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29564736 1.00 HPGD (0.55) HPGDMGLLDDR1CYP1A2CYP3A4
SCHEMBL23675308 0.91 HPGD (0.55) HPGDMGLLDDR1CYP1A2CYP3A4
SCHEMBL30201394 0.88 HPGD (0.61) HPGDMGLLDDR1CYP1A2CYP3A4
SCHEMBL24942913 0.88 HPGD (0.61) HPGDMGLLDDR1CYP1A2CYP3A4
SCHEMBL29564747 0.86 HPGD (0.61) HPGDMGLLDDR1CYP1A2CYP3A4
SCHEMBL23675344 0.86 HPGD (0.61) HPGDMGLLDDR1CYP1A2CYP3A4
SCHEMBL29565010 0.86 HPGD (0.56) HPGDMGLLDDR1CYP1A2CYP3A4
SCHEMBL23675343 0.86 HPGD (0.56) HPGDMGLLDDR1CYP1A2CYP3A4
SCHEMBL23675325 0.85 HPGD (0.57) HPGDMGLLDDR1EGFR
SCHEMBL29565007 0.85 HPGD (0.57) HPGDMGLLDDR1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4228650-A1 INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF Epirium Bio Inc. (US) 2023-08-23 — — EP disclosed
CN-115335043-A PGDH inhibitors and methods of making and using 迈欧伏特治疗公司 2022-11-11 — — CN disclosed
US-11345702-B1 PGDH inhibitors and methods of making and using MYOFORTE THERAPEUTICS, INC. (US) 2022-05-31 — — US disclosed
WO-2022082009-A1 INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF EPIRIUM BIO INC. (US) 2022-04-21 — — WO disclosed
WO-2021151014-A1 PGDH INHIBITORS AND METHODS OF MAKING AND USING MYOFORTE THERAPEUTICS, INC. (US) 2021-07-29 — — WO disclosed
WO-2021151014-A1 PGDH INHIBITORS AND METHODS OF MAKING AND USING MYOFORTE THERAPEUTICS, INC. (US) 2021-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345702-B1 PGDH inhibitors and methods of making and using HPGD, HPGDS, PTGS1 HPGD 1/4885MGLL 494/4885DDR1 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.